EP0772778B1 - Verfahren zur bestimmung des präthrombotischen status - Google Patents

Verfahren zur bestimmung des präthrombotischen status Download PDF

Info

Publication number
EP0772778B1
EP0772778B1 EP95942622A EP95942622A EP0772778B1 EP 0772778 B1 EP0772778 B1 EP 0772778B1 EP 95942622 A EP95942622 A EP 95942622A EP 95942622 A EP95942622 A EP 95942622A EP 0772778 B1 EP0772778 B1 EP 0772778B1
Authority
EP
European Patent Office
Prior art keywords
microparticles
cells
receptor
procoagulant cells
stimulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95942622A
Other languages
English (en)
French (fr)
Other versions
EP0772778A1 (de
Inventor
Jean-Marie Freyssinet
Benedicte Antoni
Frederic Donie
Helmut Lill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Priority to EP95942622A priority Critical patent/EP0772778B1/de
Publication of EP0772778A1 publication Critical patent/EP0772778A1/de
Application granted granted Critical
Publication of EP0772778B1 publication Critical patent/EP0772778B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Definitions

  • the present invention relates to a method for determining the prethrombotic state of an individual. More specifically the present invention relates to a method for the determination of the circulating microparticles and/or stimulated procoagulant cells, to a method for the determination of a special category of circulating microparticles and/or stimulated procoagulant cells as well as to a method for the determination of phospholipid-binding antibodies which are related to diseases which are related to an increased thrombotic risk.
  • thrombosis occurs as an acute event which cannot be easily and rapidly predicted.
  • Various permissive conditions for the development of thrombotic complications have been described, inflammation being the most common.
  • Alterations of blood and/or vascular cell functions are probably at the origin of prethrombotic states and could therefore be indicative of the associated thrombotic risk provided they could be unambiguously assessed.
  • Anionic phospholipids chiefly phosphatidyl serine, are essential for normal hemostasis, but they are almost entirely sequestered in the inner leaflet of the plasma membrane of resting blood and vascular cells (Devaux P.F., Static and dynamic lipid asymmetry in cell membranes. Biochemistry 30 (1991), 1163 - 1173; Zwaal R.F.A. et al., Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem. Soc. Trans. 21 (1993), 248 - 253).
  • Their catalytic potential is due to ability to assemble the characteristic enzyme complexes of the blood coagulation cascade (Fig. 1) at the site of a wound.
  • Thrombin, collagen and, above all, the thrombin+collagen combination are the major physiological agonists of anionic phospholipid exposure in platelets. It occurs as a scrambling process responsible for membrane remodelling and microparticle shedding (Zwaal R.F.A. et al., Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem. Soc. Trans. 21 (1993), 248- 253). Phospholipid scrambling and vesiculation could be the consequence of transient elevation of intracellular calcium.
  • thrombin receptor of platelets also present in endothelial cells, stimulates calcium influx (Coughlin S.R. et al., Characterization of a functional thrombin receptor. J. Clin. Invest. 89 (1992), 351 - 355) and could then be involved in such processes.
  • the terminal membrane-attack complement complex C5b-9 could also provoke the shedding of microparticles bearing a proportion of anionic phospholipids from platelets and endothelium (Zwaal R.F.A. et al., Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem. Soc. Trans.
  • Phosphatidylserine is thought to be a determinant of reticuloendothelial recognition leading to elimination of circulating membrane debris (Allen T. et al., phosphatidyl-serine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc. Natl. Acad. Sci USA 85 (1988), 8067 - 8071).
  • phosphatidyl-serine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc. Natl. Acad. Sci USA 85 (1988), 8067 - 8071.
  • thrombin The generation of thrombin is the culminating event of the coagulation cascade, mainly due to a high potential of auto-amplification expressed in several feedback loops (Mann K.G., Krishnaswamy S. & Lawson J. H. Surface-dependent hemostasis. Semin. Hematol., 29 (1992), 213 - 226), one of them resulting in the exposure of procoagulant phospholipids by and from platelets (Zwaal R.F.A., Comfurius P. & Bevers E.M. Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem. Soc. Trans. 21 (1993), 248 - 253).
  • Excessive thrombin generation can be controlled by two different mechanisms, either by direct neutralization by anti-thrombins or by anticoagulant protein C which acquires the capacity of degrade procoagulant cofactors VIIIa & Va after activation by thrombin itself (Fig. 1) (Mann K.G., Krishnaswamy S. & Lawson J. H. Surface-dependent hemostasis. Semin. Hematol., 29 (1992), 213 - 226; Esmon C.T., The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem. 264 (1989), 4743 - 4746).
  • WO 93/24840 describes a method for determining the procoagulant activity of resting platelets based on the availability of negatively charged phospholipids in the outer membrane of platelets.
  • the amount of procoagulant phospholipids in whole blood is low, because resting platelets have a mechanism to transport phosphatidyl serine from the outer to the inner leaflet of the membrane. A minor amount of the phosphatidyl serine is probably still present in the outer leaflet causing a residual procoagulant activity of the platelets.
  • This residual or resting activity establishes a threshold at above which activated clotting factors may result in thrombosis.
  • the susceptibility of an individual to experience thrombosis may be correlated with the level of procoagulant activity of his platelets.
  • the object of the present invention was to find a simple and rapid method for the determination of the prethrombotic state of an individual and for the diagnosis of various vascular diseases such as peripheral artherial occlusion, arterosclerosis, diabetic angiopathy, vasculitis, pre-eclampsia, lupus erythematosus or angina pectoris and for the diagnosis and monitoring the state of an individual after PTCA (percutaneous transluminal coronaroangioplasty).
  • PTCA percutaneous transluminal coronaroangioplasty
  • Some auto-immune disorders and other diseases for example infection, inflammation, neoplasia myocardialinfaction strokes or transient ischaemic attacks, venous thrombosis, arterial thrombosis, pregnancy screening, connective tissue disease, thrombocytopenia, oral contraceptive therapy, migraine/ headaches or pulmonary hypertension, are correlated with the occurrence of phospholipid-binding antibodies.
  • Phospholipid-binding antibodies are heterogeneous immunoglobulins of the G, M or A class.
  • ⁇ 2-GP-I ⁇ 2-glycoprotein-I
  • prothrombin protein C
  • protein S protein S
  • Apoptosis or programmed cell death, could result in increased circulating cell fragments containing phosphatidyl-serin (so called apoptotic bodies).
  • the detection of circulating apoptotic bodies bearing exposed phosphatidylserine could be helpful for the diagnosis of high levels of in vivo apoptosis associated with major diseases such as AIDS, cancer, autoimmune disorders or artherosclerosis.
  • the level of circulating apoptotic bodies could be indicative of the development or evolution of the disease especially, if the cellular origin of the microparticles can be determined.
  • a simple and rapid method for determining the Prethrombotic state of an individual and for the diagnosis of various vascular diseases such as peripheral artherial occlusion, artheriosclerosis, diabetic angiopathy, vasculitis, pre-eclampsia, lupus erythematosus or angina pectoris and for the diagnosis and monitoring the state of an individual after PTCA (percutaneous transluminal coronaroangioplasty) by determining the circulating microparticles and/or stimulated procoagulant cells.
  • PTCA percutaneous transluminal coronaroangioplasty
  • a method for determining the circulating microparticles and/or stimulated procoagulant cells by mixing a sample containing said circulating microparticles and/or stimulated procoagulant cells with a specific receptor for a compound exposed on said microparticles and procoagulant cells which receptor is bound directly or indirectly to a solid phase under conditions to form a complex of the solid phase bound receptor and the microparticle or procoagulant cell, separating the solid phase from the liquid phase and determining the amount of microparticles and/or procoagulant cells on the solid phase or after separation of the solid phase by appropriate methods (Fig. 2).
  • the present invention there is also provided a method for determining the circulating microparticles and/or stimulated procoagulant cells by mixing a sample containing said circulating microparticles and/or stimulated procoagulant cells with a specific receptor for a compound exposed on said circulating microparticles and/or stimulated procoagulant cells under conditions to form a complex of the circulating microparticles and/or stimulated procoagulant cells and the receptor and determining the amount of microparticles and/or stimulated procoagulant cells by appropriate methods.
  • the receptor must be at least bivalent.
  • the amount of microparticles and/or stimulated procoagulant cells could be determined by nephelometric or turbidimetric measurement.
  • a variation of the above assay can be used for determining a special category of circulating microparticles and/or stimulated procoagulant cells by mixing a sample containing said circulating microparticles and/or stimulated procoagulant cells with a specific receptor 1 for a compound exposed on said microparticles and stimulated procoagulant cells which receptor is bound directly or indirectly to a solid phase under conditions to form a complex of the solid phase bound receptor 1 and the microparticle or procoagulant cell, optionally separating the solid phase from the liquid phase, binding of a receptor 2 to the microparticles and/or the procoagulant cells which receptor 2 is specific for a marker of the special category of microparticles and stimulated procoagulant cells and determining the complex of receptor 1, microparticles or stimulated procoagulant cell and receptor 2 by appropriate methods (Fig. 2).
  • the sample is mixed with a receptor for a subgroup-specific compound exposed on said microparticles and/or stimulated procoagulant cells and determining the binding of circulating microparticles or stimulated procoagulant cells to said receptor by appropriate methods.
  • the subgroup-specific receptor must be directed to a compound which is exposed only on circulated microparticles and/or stimulated procoagulant cells and not on resting cells.
  • Examples for these receptors are annexin-V for exposed procoagulant phospholipid patch, specific antibodies to the active/functional conformation of the platelet membrane glycoprotein complex GPIIb/IIIa, or the monocyte or lymphocyte adhesive receptor LFA-1, or endothelial thrombomodulin.
  • a variation of the above assay can be used for the detection of phospholipid-binding antibodies in a blood sample mixing the blood sample with microparticles and/or stimulated procoagulant cells or synthetic phospholipid-containing liposomes under conditions to allow the binding of phospholipid-binding antibodies present in said blood sample to said microparticles, stimulated procoagulant cells or synthetic phospholipid-containing liposomes determining the phospholipid-binding antibodies by appropriate methods (Fig. 3).
  • the detection and characterization of stimulated or activated blood and/or vascular cells and shed procoagulant microparticles can be considered as a key step in the understanding of the pathogenesis of thrombosis. Circulating stimulated or activated (the two terms could be used for the same expression) procoagulant cells or fragments and microparticles derived therefrom appear as markers of prethrombotic states and also disseminate coagulation reactions. Such a dual behaviour requires assessment on quantitative and qualitative basis. The detection procedure has to be fast to allow appropriate prevention of the development of thrombosis.
  • the invention provides a method for determining the prethrombotic state of an individual and for the diagnosis of various vascular diseases and risk factors and for monitoring the state of an individual after PTCA by determining the circulating microparticles and/or stimulated procoagulant cells.
  • microparticles means small particles which are derived from stimulated procoagulant cells mainly platelets by microparticle shedding (Zwaal R.F.A. et. al., Mechanism and function of changes in membrane-phospholipid asymmetry in platelets and erythrocytes. Biochem. Soc. Trans. 21 (1993), 248 - 253).
  • procoagulant cells means whole stimulated procoagulant cells as well as fragments thereof which expose anionic phospholipids on their outer surface.
  • microparticles within this definition includes also apoptotic bodies of various origin as described above.
  • microparticles and/or stimulated procoagulant cells any appropriate method such as homogeneous or heterogeneous immunoassays or functional assays could be used.
  • the first step of the present method is a binding of these microparticles or cells to a solid phase via binding to a specific receptor. Thereby a concentration and separation of these microparticles and cells from other blood cells and other blood or vascular compounds is possible.
  • microparticles and/or stimulated procoagulant cells by a homogeneous method without an intermediate separation step.
  • the microparticles and/or stimulated procoagulant cells could be precipitated or agglutinated by a receptor which is at least bivalent.
  • the precipitation or agglutination could be measured directly for example by nephelometric or turbidimetric measurement.
  • concentration by other homogeneous methods such as an (electro)chemiluminescent method (EP-A-0 580 979, WO 87/06706).
  • the receptor can also be monovalent.
  • any receptor which binds to a naturally occurring molecule on the surface of the microparticles and stimulated procoagulant cells could be used.
  • a molecule must be specific for the microparticles and stimulated procoagulant cells. Specific means that this molecule or marker must be exposed only on these microparticles or cells and not on resting cells e.g. resting platelets or that this molecule or marker is exposed in a larger amount on the surface of the microparticles or stimulated cells compared to the precursor cells.
  • the receptor is directed to the phospholipids on the surface of the microparticles and stimulated procoagulant cells.
  • Annexin especially Annexin-V, a phospholipid- and calcium-binding protein also referred to as placental anticoagulant protein-I or vascular anticoagulant- ⁇
  • placental anticoagulant protein-I or vascular anticoagulant- ⁇
  • vascular anticoagulant- ⁇ a phospholipid- and calcium-binding protein also referred to as placental anticoagulant protein-I or vascular anticoagulant- ⁇
  • annexin-V behaves as a strong antagonist of phospholipid-dependent coagulation reactions due to its potent ability to compete with vitamin K-dependent proteins for binding to anionic phospholipid surfaces (Ravanat C. et al., A neutron solution scattering study of the structure of annexin-V to demonstrate the role of phosphatidylserine exposure in the maintenance of haemostatic balance by endothelial cells. Biochem J. 282 (1992), 7 - 13).
  • annexin-V could be used in a diagnostic method for the determination of microparticles and/or stimulated procoagulant cells without negatively altering the phospholipid-dependent coagulation reaction.
  • Other specific receptors are for example phospholipid-binding antibodies or antibodies directed to proteins embedded in the phospholipids of the microparticles.
  • the specific receptors such as annexin, especially annexin-V or specific antibodies to compounds exposed on the surface of microparticles and stimulated procoagulant cells could be coated directly to the surface of a solid phase by methods known in the art such as adsorption or covalent coupling via bifunctional agents.
  • the indirect binding of the specific receptors to the solid phase is preferred because thereby it is possible to use universally coated solid phases such as streptavidin-coated solid phases and because a preincubation of the specific receptor with the sample in liquid phase is possible. In some cases thereby the binding of the receptor to the microparticles and/or stimulated procoagulant cells could be enhanced.
  • the specific receptor is bound in this case to the solid phase via a specific binding pair comprising of a first and a second binding pair member (bpm).
  • the first bpm is attached to the solid phase and the second bpm is coupled to the specific receptor.
  • specific binding pairs are known in the art for example hapten/antibody, enzyme/substrate, enzyme/inhibitor, antigen/antibody, avidin or streptavidin/biotin and sugar/lectin.
  • the use of avidin or streptavidin/biotin as the specific binding pair is preferred (Fig. 2).
  • microtiterplates or microcarriers made of plastics for example polystyrol, polyvinyl, polypropylene, polycarbonate, polysaccharide, silicone or glass (E. T. Maggio, Enzyme Immunoassays, CAP. Press, Florida (1980), 175 - 180, EP-A-0 063064, Bioengineering 16 (1974), 997 - 1003 and Sonderson and Wilson, Immunology 20 (1971), 1061 - 1065).
  • the microcarriers could be used as small columns.
  • sample it is possible to use whole blood or plasma. It is especially preferred to use platelet poor plasma.
  • the sample is supplemented with an anticoagulant solution containing for example thrombin and factor Xa inhibitors.
  • the composition of the anticoagulant solution for collection of blood samples should keep platelet activation at a level as low as possible.
  • the microparticles and/or stimulated procoagulant cells are captured by incubating the sample with the specific receptor attached to the solid phase or by incubating the sample with a soluble specific receptor and thereafter attaching the receptor to the solid phase.
  • the incubation period depends on the specific receptor i.e. its affinity, and the shape of the solid phase.
  • an incubation period of about 30 minutes at room temperature is appropriate.
  • free calcium ions should be present during the incubation in an amount of at least 1 mM but not exceeding 10 mM.
  • a buffer solution with physiological salt concentrations and calcium ions for example 50 mM Tris buffer, pH 7,5 containing 0,1 M NaCl and 1 mM CaCl 2 could be used.
  • the amount of these compounds could be determined directly on the solid phase or after the separation of the compounds from the solid phase.
  • tubes or microtiterplates as solid phase it is preferred to determine the amount directly on this solid phase.
  • a short column filled with microcarriers as solid phase it is preferred to eluate the microparticles and/or activated cells from the column and thereafter determine the amount in the eluant.
  • microparticles and/or stimulated procoagulant cells are determined via their procoagulant activity which is based on the availability of anionic phospholipids in the outer membrane of the microparticles and/or stimulated procoagulant cells (Fig. 2).
  • the microparticles and/or stimulated procoagulant cells are incubated with a substrate which can be activated by an enzyme or enzyme complex which is procoagulant phospholipid-dependent, such as prothrombin (factor II). Further enzymes, coenzymes and cations such as factor V, factor Xa and calcium-ions, which are required for the activation reaction are added.
  • the prothrombin activation is linearly dependent on the amount of procoagulant anionic phospholipids in the sample. It is preferred to incubate the microparticles and/or stimulated cells in a first step with a mixture of the necessary enzymes, coenzymes and cations for example prothrombin (factor II), factor V, factor Xa and calcium ions. After a predetermined incubation period the activation of prothrombin (factor II) to thrombin (factor IIa) is stopped for example by the complexation of calcium-ions. EDTA is a preferred complexation agent. Thereafter a chromogenic substrate that could be hydrolysed by thrombin is added and the liberation of the chromophore is measured by recording the absorbance change.
  • Chromogenic substrates for thrombin are well known in the art for example Chromozym® TH (Tos-Gly-Pro-Arg-p-nitroanilide-dehydrochlorid) or D-Phepipecolyl-Arg-p-nitroanilidedihydrochlorid.
  • the phospholipid-dependent prothrombin-converting activity assay was adapted from Connor J. et al., Differentiation-dependent expression of phosphaditylserine in mammalian plasma membranes: Quantitative assessment of outer leaflet lipid by prothrombinase complex formation. Proc. Natl. Acad. Sci. USA 86 (1989), 3184 - 3188.
  • Concentration of the various reagents is such that linearity is preserved over a wide concentration range of exposed procoagulant phospholipids.
  • the preferred final concentration of each compound is 2.5 ⁇ M for factor II, 33 pM for factor V, 11 pM for factor Xa, 1.3 mM for CaCl 2 , 5mM for EDTA, and 70 ⁇ M for Chromozym® TH (Connor J. et al., Differentiation-dependent expression of phosphaditylserine in mammalian plasma membranes: Quantitative assessment of outer leaflet lipid by prothrombinase complex formation. Proc. Natl. Acad. Sci. USA 86 (1989), 3184 - 3188) The determination of the microparticles and/or stimulated cells via their procoagulant activity could be used generally e.g. microparticles and/or cells bound to solid phase or liberated of from solid phase.
  • a second receptor which is specific for a molecule on the surface of the microparticles and/or stimulated procoagulant cells.
  • the detection is carried out by a sandwich-assay which is well known in the art.
  • the second receptor could be the same as the first receptor or it could be directed against a different molecule or epitope exposed on the surface of the microparticles and/or stimulated procoagulant cells.
  • This molecule exposed on the surface of the microparticles and/or stimulated procoagulant cells could be a molecule that is specific for these cells i. e. a molecule that is not or much less present on resting cells.
  • This molecule could also be a common molecule exposed on stimulated and resting cells. It is only necessary that one of the two receptors used in the sandwich assay is specific for the microparticles and/or stimulated procoagulant cells. This could be the first or the second receptor.
  • receptors directed to compounds which are common to all microparticles and/or stimulated procoagulant cells.
  • the second receptor is an antibody or annexin-V.
  • Preferred are antibodies directed to anionic phospholipids (Rote et al., Immunologic detection of phosphadityl serine externalization during thrombin-induced platelet activation, Clin. Immunol. Immunopathol. 66 (1993), 193 - 200; Nomura et al. Anti-phospholipid antibodies bind to platelet microparticles in idiopathic autoimmune thrombocytopenic purpura. Ann. Hematol.
  • Annexin-V as a probe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups. Blood 81 , 2554 - 2565).
  • the binding of the second receptor is detected by appropriate methods.
  • the second receptor could be labelled by an enzyme, (electro)chemiluminescent, fluorescent or any other label.
  • an indirect label i. e. a receptor for example an antibody directed against the second receptor which is labelled with the above mentioned labels.
  • This indirect label has the advantage that a "universal label" for example a labeled anti-Fc antibody could be used. Examples and methods for the directly or indirectly labeling of the second receptor are known in the art (Coligan J. E., Kruibeek A. M., Margulies D.H., Shevach E.M., and Strober W. (1992, 1994) Current protocols in Immunology - Wiley Interscience - New York).
  • the sample is incubated with a specific receptor.
  • This receptor must be directed to a molecule which is common to all microparticles and/or stimulated procoagulant cells for example anionic phospholipids.
  • the receptor In the case of an agglutination or precipitation reaction the receptor must be at least bivalent to allow the bridging of at least two microparticles and/or stimulated procoagulant cells which results in a precipitation or agglutination.
  • the receptor is preferably an antibody. It is also possible to use monovalent receptors such as annexin-V or bivalent receptors which are cross-linked or coupled to carriers to produce receptor-complexes which are at least bivalent. Methods for cross-linking of receptors or coupling of receptors to carriers such as bovine serum albumin, dextrans, polysaccharides or latex particles are known in the art.
  • the precipitation or agglutination of the receptor - microparticles and/or stimulated procoagulant cell-complexes are determined preferably by nephelometric or turbidimetric methods.
  • the first receptor is directed to a compound common to all microparticles and/or stimulated procoagulant cells and the second receptor is directed to a compound, molecule or marker on the surface of the microparticles and stimulated procoagulant cells which is common to a subgroup or category of microparticles and stimulated cells (Fig. 2).
  • Fig. 2 the second receptor is directed to a compound, molecule or marker on the surface of the microparticles and stimulated procoagulant cells which is common to a subgroup or category of microparticles and stimulated cells.
  • a further embodiment of the present invention is therefore a method for the determination of a subgroup or category of circulating microparticles and/or stimulated procoagulant cells by mixing a sample containing said circulating microparticles and/or stimulated procoagulant cells with a specific receptor 1 for a compound exposed on said microparticles and stimulated procoagulant cells which receptor is bound directly or indirectly to a solid phase under conditions to allow the formation of a complex of solid phase bound receptor 1 and microparticle or procoagulant cell, optionally separating the solid phase from the liquid phase, binding of a receptor 2 to the microparticles and/or procoagulant cells which receptor 2 is specific for a marker of the category or subgroup of microparticles and procoagulant cells and determining the complex of receptor 1, microparticle or stimulated procoagulant cell or receptor 2 by appropriate methods.
  • receptor 2 it is preferred to use an antibody against a subgroup-specific marker, molecule or compound on the surface of the microparticles and stimulated cells.
  • markers are for thrombocytes GPIb, GPIX, GPIIb/IIIa, thrombospondin or for endothelial cells, thrombomodulin or for monocytes CD14 or TF (tissue factor which could also be found on micorparticles shed from stimulated endothelium) or GMP 140 (P-selectin) which is found both on activated platelets and endothelial cells or CD4 and DC11a for apoptotic bodies.
  • a further embodiment of the present invention is a modification of this assay for the determination of the subgroup of circulating microparticles and/or stimulated procoagulant cells.
  • This method for the determination of subgroups of microparticles and/or stimulated procoagulant cells comprises mixing a sample with a receptor for a subgroup-specific compound expose on the microparticles and stimulated procoagulant cells and determining the binding of this receptor by appropriate methods.
  • a receptor for a subgroup-specific compound means a receptor that is directed to a compound, molecule or marker which is only present on the subgroup and is not or much less present on other subgroups of microparticles and/or stimulated procoagulant cells and resting cells for example resting platelets, monocytes or endothelial cells.
  • some phospholipid-binding antibodies are directed to proteins in connection with phospholipids, i.e. they do not bind much to the protein or the phospholipid alone.
  • This binding of this subgroup-specific receptor to the microparticles and/or stimulated procoagulant cells could be determined by known methods.
  • the subgroup-specific receptor could be for example bound directly or indirectly to a solid phase as described above. After capturing the microparticles and/or stimulated procoagulant cells of a special subgroup the amount could be determined directly on the solid phase or after their separation from the solid phase as described above for example via their procoagulant activity (prothromin assay) or via a second receptor which is specific for the microparticles and/or stimulated procoagulant cells or a receptor which is specific for a marker on resting cells such as platelets, monocytes or endothelial cells.
  • the binding of the subgroup-specific receptor could also be determined directly via the precipitation or agglutination of the microparticles and/or stimulated procoagulant cells by this receptor which must be in this case at least bivalent as described above.
  • the subgroup-specific receptor is coupled to particles such as latex particles.
  • the microparticles and/or stimulated procoagulant cells can be obtained from human blood or plasma especially from human platelet poor plasma. It is also possible to use microparticles and/or stimulated procoagulant cells from blood or plasma of an animal since phospholipids are ubiquitous components. It is preferred to use synthetic liposomes containing phospholipids in their membrane. Methods for the production of liposomes are known in the art for example Freyssinet et al., Biochem. J. (1989), 261 , 341 - 348. A preferred method is to use liposomes made of a mixture of phosphatidyl serine and phosphatidyl choline (1 : 2) prepared by the dialysis method according to Freyssinet et al. (above).
  • microparticles and/or stimulated procoagulant cells or liposomes can be bound to a solid phase preferably by receptors to phospholipids i. e. phospholipid-binding antibodies or annexin-V.
  • the receptors could be bound directly or indirectly to the solid phase as described above (Fig. 3).
  • the microparticles, stimulated procoagulant cells or liposomes are bound to a solid phase via streptavidin or avidin/biotin. Streptavidin- or avidin-coated solid phases are known in the art.
  • the microparticles or procoagulant cells or liposomes are biotinylated. Biotinylation of these microparticles, cells or liposomes can be done by incorporation of biotinylated phospholipids into the membrane of these particles. This could be done by simply adding to the microparticles, stimulated procoagulant cells or liposomes biotinylated phospholipids for example biotinylated phosphatidyl ethanolamine or phosphatidyl choline.
  • the biotinylated phospholipids are inserted into the membrane of the particles. It is especially preferred to use this method for attaching synthetically produced liposomes to solid phase.
  • the liposomes are produced by adding for example 1 % biotinylated phosphatidyl ethanolamine or biotinylated phosphatidyl choline to the other phospholipids.
  • the circulating microparticles and/or stimulated procoagulant cells or synthetic phospholipid-continging liposomes are bound to a annexin-V-coated solid phase as described above (Fig. 3).
  • the blood sample under examination is mixed with the microparticles and/or procoagulant cells or liposomes under conditions to allow the binding of phospholipid-binding antibodies in said blood sample to the particles and to allow the binding of the particles to the solid phase in the case of an indirect attachment.
  • the particles could be attached to the solid phase simultaneously, before or after the binding of the antibodies to the particles.
  • the phospholipid-binding antibodies which are bound to the solid phase via the microparticles, stimulated procoagulant cells or liposomes are determined by appropriate methods.
  • the bound phospholipid-binding antibodies by specific labelled receptors to the phospholipid-binding antibodies such as anti-Fc antibodies, anti-human immunglobuline antibodies, anti-human-IgA, G, M-antibodies, anti-light-chain-antibodies, protein A or protein G.
  • specific receptors for the phospholipid-binding antibodies could be labelled directly or indirectly as described supra.
  • This method for the determination of phospholipid-binding antibodies can be variated to detect special subgroups of phospholipid-binding antibodies. It is known that some auto-antibodies are specific for a complex of phospholipids and special proteins which are incorporated or bound to the membrane of the microparticles and/or stimulated procoagulant cells. It is thereby possible to assess combinations of phospholipid-containing particles and phospholipid-binding proteins from plasma for example ⁇ 2-glycoprotein 1, prothrombin, protein S or protein C as possible antigens responsible for the anti-phospholipid syndrome characterized by the presence of corresponding reactive antibodies.
  • the first advantage of this system is its versatility with respect of phospholipids of various composition to be assayed in combination with the above mentioned phospholipid-binding proteins.
  • the second is that it allows to assay the possible in vitro anticoagulant potential of some phospholipid-binding antibodies using the same support as that enabling their detection.
  • microparticles and/or stimulated procoagulant cells or synthetic phospholipid-containing liposomes which further comprise these mentioned proteins it is possible to determine subgroup-specific phospholipid-binding antibodies (Fig. 3).
  • the proteins can be incorporated into the phospholipid-containing particles as integral or peripheral membrane proteins ( ⁇ 2 -glycoprotein-I, prothrombin, protein S, protein C, etc).
  • Figure 1 shows the blood coagulation system .
  • Figure 2 shows the principle of the detection of circulating microparticles or stimulated procoagulant cells or cell fragments by an ELISA of CD's and/or GP's or by prothrombinase activity.
  • Figure 3 shows the principle of the detection of phospholipid-binding antibodies by ELISA of APL (phospholipid-binding antibody).
  • Figure 4 shows the effect of the biotinylated ratio of annexin-V on the prothrombinase assay
  • Figure 5 shows the effect of the biotinylated annexin-V (AV-Bi) concentration on the prothrombinase assay
  • Figure 6 shows the effect of the phospholipid concentration on the prothrombinase assay.
  • Figure 7 shows the prothrombinase activity in the supernatant of U937 cells treated with oxysterols for the induction of apoptosis.
  • Figure 8 shows the detection of specific membrane antigen CD11a present at the surface of microparticles captured by biotinylated annexin Va complexed to SA-coated microtiterplates.
  • Figure 9 shows capture of microparticles bearing specific antigens by corresponding insolubilized antibodies.
  • Figure 10 shows procoagulant microparticle detection in plasma from patients with PNH.
  • Figure 11 shows immobilization of different phospholipd antigens onto streptavidin-coated microtitration plates for solid phase detection of phospholipid-binding antibodies.
  • SA and B1 stand for streptavidin and biotin respectively.
  • Human blood coagulation factor X and prothrombin were purified from vitamin K-dependent protein concentrates free of common viral contaminants (Freyssinet J.-M. et al., Interference of blood coagulation vitamin K-dependent proteins in the activation of human protein C. Biochem J. 256 (1988), 501 - 507).
  • Human ⁇ -thrombin (3,000 National Institutes of Health (NIH) units/mg of protein) was prepared from purified prothrombin according to Freyssinet J.-M. et al., Interference of blood coagulation vitamin K-dependent proteins in the activation of human protein C. Biochem J. 256 (1988), 501 - 507.
  • Factor Xa was obtained from purified factor X as described in Freyssinet J.-M. et al., Activation of human protein C by blood coagulation factor Xa in the presence of anionic phospholipids. Biochem J. 261 (1989), 341 - 348.
  • Factor V was purchased from Diagnostica Stago (Asbecks, France).
  • Human placenta annexin V (placental anticoagulant protein-I) was purified according to Funakoshi et al. (Funakoshi T. et al., Human placental anticoagulant protein: isolation and characterization. Biochemistry 26 (1987) 5572 - 5578) and characterized as published in Ravanat C.
  • Fluorescent membrane probe (red fluorescence) 1,1'-dihexadecyl-3,3,3',3'-tetramethyl indocarbocyanine (DiIC 16 (3)) was from Molecular Probes (Eugene, OR).
  • Chromogenic substrates N- ⁇ -benzylocarbonyl-D-arginyl-L-glycyl-L-arginine-p-nitroanilide-dihydrochloride (S-2765) and H-D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydrochloride (S-2238) were purchased from Chromogenix AB (Mölndal, Sweden).
  • D-Phenylalanyl-Prolyl-Arginyl chloromethyl ketone (PPACK) and 1,5-dansyl-Glutamyl-Glycyl-Arginyl chloromethyl ketone (Dns-GGACK), two potent irreversible inhibitors of thrombin and factor Xa respectively, were obtained from Calbiochem (San Diego, CA). All other reagents were of the highest available purity grade.
  • Reference liposomes made of 33% phosphatidyl serine and 67% phosphatidyl choline (mol/mol) were prepared by the dialysis method according to Freyssinet J.-M. et al., Activation of human protein C by blood coagulation factor Xa in the presence of anionic phospholipids. Biochem J. 261 ( 1989), 341 - 348.
  • phospholipid vesicle preparation (phosphatidyl serine/phosphatidyl choline 33/66 (mol/mol) 3 mM) the following reagents were used:
  • the DiC 16 (3) probe was added to the phospholipid mixture at a final molar ratio of 0.1% before dialysis which allowed its incorporation into the resulting bilayer structures.
  • the liposomes appeared mostly unilamellar, rather spherical and had a mean diameter of 150 nm, with extremes at 30 and 300 nm (Pigault C. et al., Formation of two-dimensional arrays of annexin-V on phosphatidylserine-containing liposomes. J. Mol. Biol. 236 (1994) 199-208).
  • Phospholipid molar concentrations were determined assuming an average molecular weight of 780 for each species.
  • liposomes were diluted in 50 mM Tris buffer, pH 7.5, containing 0.1 M NaCl and 1 mM CaCl 2 .
  • the characteristics of DilC 16 (3)-labeled liposomes appeared comparable to that of microparticles shed from either cell type including platelets (see below) when analyzed by flow cytometry (Dachary-Prigent J. et al., Annexin-V as aprobe of aminophospholipid exposure and platelet membrane vesiculation: A flow cytometry study showing a role for free sulfhydryl groups. Blood 81 , 2554 - 2565).
  • Plasma samples were collected by vein puncture in 0.14 M tri-sodium citrate at a final volume ratio of 9:1.
  • Platelet rich plasma PRP
  • PPP Platelet poor plasma
  • PPACK and Dns-GGACK were added to samples at a final concentration of 10 ⁇ M each.
  • Biotinylation of annexin-V was achieved at various biotin to protein molar rations ranging from 20/1 and 2/1.
  • Biotinylation buffer 75 mM KH 2 PO 4 , 200 mM NaCl, pH 7.7 Biotin solution 11.4 mM Biotin-X-OSu (MW 454.5) in DMSO Storage buffer 75 mM KH 2 PO 4 200 mM NaCl, Lysin 10 mM, pH 7.7
  • biotinylated annexin V After 90 min at 25°C, the reaction is stopped by adding 1M Lysine/HCl to a final concentration of 10 mM. The biotinylated annexin V is finally dialysed overnight at 4°C against Storage buffer. This biotinylated annexin V can be stored for months at -80°C, without detectable loss of anti-phospholipid potential.
  • Biotinylated annexin-V (annexin-V Bi ) was insolubilized onto streptavidin-coated microtitration plates by contact of 100 ⁇ l/well of annexin-V Bi solution in 50 mM Tris buffer, pH 7.5, containing 0.1 M NaCl and 3 mg/ml albumin, at concentrations ranging from 50 ng/ml to 1 ⁇ g/ml, during 30 min at room temperature. The plates were then washed 3 times with 200 ⁇ l of the above buffer and immediately used for capture of activated cells or fragments.
  • Blood clotting factor concentrations have been determined to ensure that phosphatidyl serine concentration is the rate-limiting parameter of linear reactions of activation of prothrombin to thrombin. In any case less than 20% of total protein substrate was converted into its activated form. Measurements were performed in triplicate in 96-well streptavidin-annexin-V Bi -coated microtitration plates in 50 mM Tris buffer containing 120 mM NaCl, 2.7 mM KCl, 1.5 mM CaCl 2 and 3 mg/ml albumin, adjusted to pH 7.5, in a final incubation volume of 150 ⁇ l.
  • Phosphatidyl serine presence was detected through its ability to promote the activation of prothrombin (2 ⁇ M) by factor Xa (10 pM) in the presence of factor V(a) (50 pM) and CaCl 2 (1.5 mM).
  • factor V(a) 50 pM
  • CaCl 2 1.5 mM
  • the 5-fold excess of factor V with respect to factor Xa enables to minimize the possible contribution of factor V couterpart attached to or released by cells.
  • Incubation was allowed to proceed for 2 h for platelet samples, cell suspensions and corresponding supernatants, or 15 min for control liposomes, at 37°C in either case.
  • Prothrombin activation was stopped by addition of an excess of EDTA, i.e. 3 mM final concentration. Chromogenic substrate for thrombin, S-2238 or Chromozym TH, was then added at final concentration of 0.1 mM. Linear absorbance changes recorded at 405 nm were converted to concentration of generated thrombin by reference to a standard curve constructed with known amounts of thrombin. In controls either factor Xa or prothrombin, or both were omitted.
  • Inhibition assays of prothrombinase activity by soluble annexin V were carried out by adding this phospholipid antagonist at a final concentration of 1.5 ⁇ M in the respective media just before coagulation factors. The aim of the latter verification was to ascertain the phospholipid-dependent character of the measured generation of thrombin.
  • annexin-V Bi concentration was varied between 1/2 to 1/20 while the annexin-V Bi concentration range was 50 ng/ml to 1 ⁇ g/ml.
  • Phospholipids were added under the form of liposomes at concentrations ranging from 0.03 to 300 ⁇ M.
  • annexin-V was biotinylated at a protein to biotin ratio of 1/5 and used at 400 ng/ml for complexation to insolubilized streptavidin (Fig. 5). Under these conditions saturation occurred at 60 ⁇ M phospholipid (Fig. 6) which corresponds roughly to the maximum surface packing assuming that liposomes are spherical and have an average diameter of 1,500 ⁇ . At saturation the amount of generated thrombin was ⁇ 1 nM/min.
  • annexin-V Bi In order to further ascertain the ability of insolubilized annexin-V Bi to retain cells or shed fragments bearing phosphatidyl serine exposed at their outer surface, lysed platelets, or ionophore-activated cells or corresponding supernatant were incubated in annexin-V-containing wells as described above.
  • the supernatant of platelets lysed at an initial concentration of 15 x 10 7 cells/ml was a source of procoagulant phospholipids which allowed to reach saturation under the same conditions as liposome suspension containing 60 ⁇ M phospholipid. It is interesting to emphasize that the phospholipid concentration contributed by 15 x 10 6 platelets/ml is about 130 ⁇ M, i.e. half the optimal liposome concentration. However, the proportion of phosphatidylserine in liposomes is at least three times higher than that of lysed platelets since it cannot be expected to be greater than 10% (mol/mol) in the latter case where phospholipid scrambling is considered as maximum (Zwaal R.F.A. et al., Platelets and coagulation.
  • U937 cells are grown in a humidified 5% CO 2 atmosphere at 37°C, using RPMI 1640 medium with Glutamax-I, supplemented with 10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, non-essential amino acids and gentamicin at 5 ⁇ g/ml. Cells are usually plated at an initial conentration of 1.10 5 /ml. Apoptosis induction is achieved by 40 ⁇ M 7 ⁇ hydroxycholesterol- or 5 ⁇ g/ml actinomycin D-treatment of U937 cells at 37°C during 8 to 24 hours. Cells have to be seeded at 3 to 4.10 5 cells per ml 6 h before treatment.
  • Cell supernatant is obtained by centrifugation of treated cells at 500 g during 7 min and CaCl 2 is added to a final concentration of 10 mM before addition of 200 ⁇ l/well of supernatant.
  • a control without 7 ⁇ hydroxycholesterol or actinomycin D has to be performed and culture medium containing 10% fetal calf serum should also be tested. It has to be emphasized that the content of microparticles of 10% fetal calf serum was low, probably due to removal of most of the cell fragments at sterilizing ultrafiltration. The amount of captured microparticles is determined using the prothrombinase assay.
  • Biotinylated annexin V (AV-Bi) (see example 1) was diluted to 400 ng/ml in TBS, 1 mM CaCl 2 , 3 g/l HSA. 100 ⁇ l/well were added to streptavidin-coated microtitration plates (Boehringer Mannheim GmbH) and incubated at room temperature for 30 min.. Excess of AV-Bi was eliminated by washing steps with TBS, 1 mM CaCl 2 . 200 ⁇ l/well cell supernatant as described above and CaCl 2 10 mM were added and incubated for 30 min.. After three washing steps with TBS, 1 mM CaCl 2 the prothrombinase assay was performed.
  • Prothrombinase assay (dilutions in TBS, 1 mM CaCl 2 , 3 g/l HSA) TBS, 1 mM CaCl 2 , 3 g/l HSA 90 ⁇ l/well Factor V 0.5 nM (50 nM, diluted 1/100) 10 ⁇ l/well Factor II 0,65 mg/ml (FII 1 mg/ml, diluted to 0.65 mg/ml) 20 ⁇ l/well Factor Xa 83 pM (2.9 ⁇ M diluted 1/35000) 20 ⁇ l/well CaCl 2 20 mM (1 M, diluted 1/50) 10 ⁇ l/well 2 h incubation at 37° C EDTAMg 20 mM (80 mM, diluted 1/4) 50 ⁇ l/well Chromozym-TH 1.52 mM (3.8 mM, diluted 1/2.5) 50 ⁇ l/well
  • prothrombinase activity is correlated with DNA analysis by flow cytometry (Table 2) 7 ⁇ -hydroxycholesterol treatment (hours) 0 h 8 h 10 h 12 h 20 h 22 h % of hypodiploid DNA 2.75 9.43 12.58 18.31 35.03 41.54
  • results show the exposure of phosphatidylserine associated with apoptosis, and provide evidence that the degree of cell death can be easily estimated by prothrombinase assay after capture of resulting vesicles.
  • cryolysed U937 cells were used to generate lysis fragments as described above. These apoptotic cell fragments bear CD11a as a target antigen.
  • the cells were captured by AV-bi on a SA-plate as described above and detected by POD-labeled antibodies to CD11a which are commercially available. The results are shown in Fig. 8. It was possible to detect these cells by this antibody and thereby the ridge of the cells could by detected.
  • Biotinylated antibodiy (anti CD4 or anti CD11a, Leinco Technology, diluted to 1 ⁇ g/ml in TBS, 1 mM CaCl 2 , 3 g/l HSA) are added to streptavidin-coated microtitration plates (100 ⁇ l/well) an d incubated 30 min at room temperature. Excess of biotinylated antibody was eliminated by washing steps with TBS (3 x 250 ⁇ l). Cell supernatant of U937 cells after induction of apoptosis as described above was added (200 ⁇ l/well) and incubated 2 h at room temperature. The plates were washed with TBS (3 x 250 ⁇ l).
  • Prothrombinase assay (dilutions in TBS, 1 mM CaCl 2 , 3 g/l HSA) TBS, 1mM CaCl 2 , 3 g/l HSA 90 ⁇ l/well Factor V 0.5 nM (50 nM, diluted 1/100) 10 ⁇ l/well Factor II 0,65 mg/ml (FII 1 mg/ml, diluted to 0.65 mg/ml) 20 ⁇ l/well Factor Xa 83 pM (2.9 ⁇ M diluted 1/35000) 20 ⁇ l/well CaCl 2 20 mM (1 M, diluted 1/50) 10 ⁇ l/well 2 h incubation at 37° C EDTA-Mg 2+ 20 mM (80 mM, diluted 1/4) 50 ⁇ l/well Chromozym-TH 1.52 mM (3.8 mM, diluted 1/2.5) 50 ⁇ l/well
  • the linear absorbance changes were recorded at 405 nm using a microplate reader equipped with a kinetics software.
  • the apoptotic cell derived microparticles are captured by the biotin-labelled antiCD4 or antiCD11a immobilized onto streptavidin-coated microtitration plate.
  • the amount of captured microparticles can be determined using the prothrombinase assay. The results are shown in figure 9.
  • Paroxysmal nocturnal hemoglobinuria is an acquired stem-cell disorder in which the glyoclipid-anchored membrane proteins, including the cell-surface complement inhibitors, CD55 and CD59, are partially or completely deleted from the plasma membrane of mature blood cells (45). This leads to hyperhemolysis resulting from hypersensitivity of red blood cells to activated complement. From a clinical point of view, PNH is characterised by hemolytic anemia and hypercoagulable state that frequently leads to thrombosis. The hypercoagulability has been attributed to the hemolysis itself or to platelet defects or hyperactivation.
  • the plasma samples from several patients were investigated in order to show the ability of the system to assess the thrombotic risk potentially linked to this disease.
  • prothrombinase activity could be measured when either of factor Xa or prothrombin were omitted in the prothrombinase assay and only traces of it were observed in the absence of factor V.
  • Annexin-V Bi is stable for weeks when stored below 0°C.
  • APL phospholipid-binding antibodies
  • AAII annexin II-binding antibodies
  • Phosphatidylserine is thought to be a determinant of reticuloendothelial recognition leading to elimination of circulating membrane debris (Allen T., Willimason. & Schlegel R.A. Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc. Natl. Acad. Sci. USA, 1988, 85, 8067-8071).
  • Phospholipid vesicle preparation for use in the detection of phospholipid-binding antibodies
  • 33.3 ⁇ l of Card were mixed with 33.3 ⁇ l of PC, 1.6 ⁇ l of Chol and 9.2 ⁇ l of PE-Bi on ice, evaporated under nitrogen flow at room temperature, resuspended in 500 ⁇ l of buffer B, dialysed against 3 x 500 ml of buffer A at 4°C during 18 to 24 h and stored at 4°C (no more than one month).
  • Card/PE-B1 vesicles 1 mM were diluted to 1/150 in TBS, 1 mM CaCl 2 , 3 g/l HSA, 100 ⁇ l/well were added to streptavidin-coated microtitration plates, incubated for 30 min at 4°C, washed with TBS, 1 mM CaCl 2 (4 x 200 ⁇ l/well), neutralized by 30 min incubation at 4°C with 10% bovine serum (v/v) n TBS, 1 mM CaCl 2 (100 ⁇ l/well).
  • the wells were washed with TBS, 1 mM CaCl 2 (3 x 200 ⁇ l/well), serum sample diluted to 1/100 (or more in case of strong positive) in TBS, 1 mM CaCl 2 , bovine serum 10% (v/v) was added (50 ⁇ l/well), incubated for 2 h at 4°C and washed with TBS, 1 mM CaCl 2 (3 x 200 ⁇ l/well), GAHu/IgG(H+L)HRPO diluted to 1/1000 in TBS, 1 mM CaCl 2 , bovine serum 10% (v/v) (50 ⁇ l/well) was added, incubated for 1 h at 4°C and washed with TBS, 1 mM CaCl 2 (3 x 200 ⁇ l/well). OPD at 0.4 mg/ml was added (50 ⁇ l/well), incubated for 4.5 min at room temperature and H 2 SO 4 6 N added (50 ⁇ l/well). The absorbance
  • Phospholipid vesicle preparation for use in the detection of annexin-II-binding antibodies
  • 100 ⁇ l ofPS were mixed with 300 ⁇ l of PC and 12 ⁇ l ofPE-Bi on melting ice, evaporated under nitrogen flow at room temperature, resuspended in 1700 ⁇ l of buffer B and dialysed against 3 x 500 ml of buffer A at 4°C during 18 to 24 h.
  • PS/PC/PE-Bi vesicles 25/74/1 (mol) 3 mM were diluted to 1/400 in TBS, 1 mM CaCl 2 , 3 g/l HSA, 100 ⁇ l/well were added to streptavidin-coated microtitration plates, incubated for 30 min at 4°C and washed with TBS, 1 mM CaCl 2 (3 x 200 ⁇ l/well).
  • Annexin II diluted to 10 ⁇ g/ml in TBS, 1 mM CaCl 2 , 10% bovine serum (v/v) was added (100 ⁇ l/well), incubated for 30 min at 4°C and washed with TBS, 1 mM CaCl 2 (3 x 200 ⁇ l/well). Serum sample diluted to 1/100 (or more in case of strong positive) in TBS, 1 mM CaCl 2 50 ⁇ l/well), bovine serum 10% (v/v)as added, incubated for 2 h at 4°C and washed with TBS, 1 mM CaCl 2 (3 x 200 ⁇ l/well).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (30)

  1. Verfahren zur Bestimmung zirkulierender Mikropartikel und/oder stimulierter Prokoagulationszellen, umfassend:
    (a) Mischen einer die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen enthaltenden Probe mit einem spezifischen Rezeptor für eine Verbindung, die auf den Mikropartikeln und Prokoagulationszellen präsentiert wird, wobei der Rezeptor unter solchen Bedingungen direkt oder indirekt an eine feste Phase gebunden ist, daß ein Komplex des an die feste Phase gebundenen Rezeptors und dem Mikropartikel und/oder der Prokoagulationszelle gebildet wird;
    (b) Trennen der festen Phase von der flüssigen Phase;
    (c) Bestimmen der Menge an Mikropartikeln und/oder Prokoagulationszellen auf der festen Phase oder nach Abtrennung der festen Phase mit Hilfe geeigneter Methoden.
  2. Verfahren nach Anspruch 1, wobei der spezifische Rezeptor bei Schritt (a) Annexin V ist.
  3. Verfahren nach Anspruch 2, wobei Calcium-Ionen bei Schritt (a) zugesetzt werden.
  4. Verfahren nach den Ansprüchen 1 bis 3, wobei der spezifische Rezeptor über ein spezifisches Bindungspaar an die feste Phase gebunden ist, umfassend ein erstes und zweites Bindungspaarelement (Bpe), wobei das erste Bpe an die feste Phase gebunden ist und das zweite Bpe mit dem spezifischen Rezeptor verknüpft ist.
  5. Verfahren nach Anspruch 1, wobei in Schritt (c) die Menge an Mikropartikeln und/oder Prokoagulationszellen durch Erfassen der Aktivierung von Prothrombin (Faktor II) zu Thrombin (Faktor IIa) bestimmt wird.
  6. Verfahren nach Anspruch 5, wobei in Schritt (a) Hemmstoffe für Thrombin und/oder Faktor Xa anwesend sind.
  7. Verfahren nach den Ansprüchen 5 und 6, wobei die Aktivierung von Prothrombin zu Thrombin erfaßt wird durch Mischen der Mikropartikel und/oder Prokoagulationszellen mit einem Faktor V, Faktor Xa, Prothrombin (Faktor II) und Calcium-Ionen umfassenden Reagens über eine geeignete Zeitspanne, Anhalten der Reaktion durch Komplexieren der Calcium-Ionen, und Bestimmen des Thrombins anhand seiner Fähigkeit, ein chromogenes Substrat zu hydrolysieren.
  8. Verfahren zur Bestimmung zirkulierender Mikropartikel und/oder stimulierter Prokoagulationszellen, umfassend:
    (a) Mischen einer die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen enthaltenden Probe mit einem spezifischen Rezeptor für eine Verbindung, die auf den zirkulierenden Mikropartikeln und stimulierten Prokoagulationszellen präsentiert wird, wobei der Rezeptor wenigstens bivalent ist unter Bedingungen, bei denen ein Komplex aus den zirkulierenden Mikropartikeln und/oder stimulierten Prokoagulationszellen und dem Rezeptor gebildet wird;
    (b) Bestimmen der Menge an Mikropartikeln und/oder stimulierten Prokoagulationszellen durch nephelometrische oder turbidimetrische Messung.
  9. Verfahren zur Bestimmung zirkulierender Mikropartikel und/oder stimulierter Prokoagulationszellen, umfassend:
    (a) Mischen einer die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen enthaltenden Probe mit einem spezifischen Rezeptor für eine Verbindung, die auf den zirkulierenden Mikropartikeln und stimulierten Prokoagulationszellen präsentiert wird, wobei der Rezeptor unter solchen Bedingungen auf Partikel aufgebracht wird, daß ein Komplex aus den zirkulierenden Mikropartikeln und/oder stimulierten Prokoagulationszellen und dem Rezeptor gebildet wird;
    (b) Bestimmen der Menge an Mikropartikeln und/oder stimulierten Prokoagulationszellen.
  10. Verfahren nach Anspruch 9, wobei der spezifische Rezeptor ein mit Annexin V überzogenes Partikel ist.
  11. Verfahren nach Anspruch 9, wobei das mit Rezeptor überzogene Partikel ein mit Avidin oder Streptavidin überzogenes Partikel ist, woran ein biotinylierter Rezeptor gebunden ist.
  12. Verfahren zur Bestimmung einer speziellen Kategorie oder Untergruppe zirkulierender Mikropartikel und/oder stimulierter Prokoagulationszellen, umfassend:
    (a) Mischen einer die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen enthaltenden Probe mit einem spezifischen Rezeptor 1 für eine Verbindung, die auf den Mikropartikeln und stimulierten Prokoagulationszellen präsentiert wird, wobei der Rezeptor unter solchen Bedingungen direkt oder indirekt an eine feste Phase gebunden ist, daß ein Komplex des an die feste Phase gebundenen Rezeptors 1 und dem Mikropartikel oder der stimulierten Prokoagulationszelle gebildet wird;
    (b) gegebenenfalls Abtrennen der festen Phase von der flüssigen Phase;
    (c) Binden eines Rezeptors 2 an die Mikropartikel und/oder Prokoagulationszellen, wobei Rezeptor 2 für einen Marker der speziellen Kategorie oder Untergruppe der Mikropartikel und stimulierten Prokoagulationszellen spezifisch ist;
    (d) Bestimmen des Komplexes aus Rezeptor 1, Mikropartikeln oder stimulierten Prokoagulationszellen und Rezeptor 2 mit Hilfe geeigneter Methoden.
  13. Verfahren nach Anspruch 12, wobei die Schritte (a) und (c) gleichzeitig durchgeführt werden.
  14. Verfahren nach den Ansprüchen 12 und 13, wobei Rezeptor 2 ein Antikörper gegen einen Thrombozyten-Marker wie etwa GPIb, GPIX, GPIIb/IIIa, Thrombospondin oder einen Marker für Endothelzellen wie etwa Thrombomodulin oder einen Marker für Monozyten wie etwa CD 14 ist.
  15. Verfahren zur Bestimmung einer speziellen Kategorie oder Untergruppe zirkulierender Mikropartikel und/oder stimulierter Prokoagulationszellen, umfassend:
    (a) Mischen einer die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen enthaltenden Probe mit einem Rezeptor für die untergruppenspezifische Verbindung, die auf den zirkulierenden Mikropartikeln und stimulierten Prokoagulationszellen präsentiert wird, wobei der Rezeptor direkt oder indirekt an eine feste Phase gebunden ist;
    (b) Bestimmen der Bindung der zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen an den Rezeptor mit Hilfe geeigneter Methoden.
  16. Verfahren nach Anspruch 15, wobei die feste Phase ein Partikel wie etwa ein Latexpartikel ist, und die Bestimmung der Bindung der zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen an den Rezeptor durch Messen der Agglutination der Partikel durchgeführt wird.
  17. Verfahren nach Anspruch 15, wobei nach Schritt (a) die feste Phase von der flüssigen Phase getrennt wird.
  18. Verfahren nach Anspruch 17, wobei in Schritt (b) die Bindung durch Erfassen der Aktivierung von Prothrombin (Faktor II) zu Thrombin (Faktor IIa) bestimmt wird.
  19. Verfahren zur Bestimmung Phospholipid-bindender Antikörper in einer Probe, umfassend:
    (a) Mischen der Blutprobe mit Mikropartikeln und/oder Prokoagulationszellen oder synthetischen Phospholipid-haltigen Liposomen unter Bedingungen, die das Binden von in der Blutprobe vorhandenen Phospholipid-bindenden Antikörpern an die Mikropartikel oder stimulierten Prokoagulationszellen oder synthetischen Phospholipid-haltigen Liposomen ermöglichen;
    (b) Bestimmen der Bindung der Phospholipid-bindenden Antikörper mit Hilfe geeigneter Methoden.
  20. Verfahren nach Anspruch 19, wobei in Schritt (b) die Antikörper durch Messen der Abscheidung der zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen oder synthetischen Phospholipid-haltigen Liposomen bestimmt werden.
  21. Verfahren nach Anspruch 19, wobei die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen oder synthetischen Phospholipid-haltigen Liposomen an eine feste Phase gebunden sind.
  22. Verfahren nach Anspruch 21, wobei biotinylierte zirkulierende Mikropartikel und/oder stimulierte Prokoagulationszellen oder synthetische Phospholipid-haltige Liposomen an eine mit Streptavidin oder Avidin überzogene feste Phase gebunden sind.
  23. Verfahren nach Anspruch 22, wobei die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen und synthetischen Phospholipid-haltigen Liposomen durch Zugabe von biotinyliertem Phosphatidylethanolamin oder biotinyliertem Phosphatidylcholin biotinyliert werden.
  24. Verfahren nach Anspruch 22, wobei die synthetischen Phospholipid-haltigen Liposomen biotinyliert werden indem die Liposomen in Gegenwart von biotinyliertem Phosphatidylethanolamin und/oder biotinyliertem Phosphatidylcholin erzeugt werden.
  25. Verfahren nach Anspruch 21, wobei die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen oder synthetischen Phospholipid-haltigen Liposomen an eine mit Annexin V überzogene feste Phase gebunden sind.
  26. Verfahren nach den Ansprüchen 19 bis 25, wobei die zirkulierenden Mikropartikel und/oder stimulierten Prokoagulationszellen oder synthetischen Phospholipid-haltigen Liposomen des weiteren Proteine umfassen, beispielsweise β2-Glycoprotein 1, Prothrombin, Protein S oder Protein C.
  27. Verfahren zur Diagnose von Krankheiten, die mit Zellschädigung oder Zelltod einhergehen, etwa AIDS, Krebs oder paroxysmale nächtliche Hämoglobinurie, durch Bestimmen der zirkulierenden apoptotischen Körper unter Verwendung eines spezifischen Rezeptors für eine präsentierte Verbindung auf diesen apoptotischen Körpern.
  28. Prüfset zur Bestimmung zirkulierender Mikropartikel und/oder stimulierter Prokoagulationszellen, umfassend:
    einen spezifischen Rezeptor für eine auf den Mikropartikeln und Prokoagulationszellen präsentierte Verbindung, der an eine feste Phase gebunden ist oder daran gebunden werden kann;
    sowie weitere Verbindungen, die zur Bestimmung der Quantität der Bindung des spezifischen Rezeptors an die Mikropartikel und Prokoagulationszellen erforderlich sind.
  29. Prüfset zur Bestimmung einer speziellen Kategorie oder Untergruppe zirkulierender Mikropartikel und/oder Prokoagulationszellen, umfassend:
    einen Rezeptor, der für einen Marker der speziellen Kategorie oder Untergruppe der Mikropartikel und stimulierten Prokoagulationszellen spezifisch ist, der an eine feste Phase gebunden ist oder daran gebunden werden kann;
    sowie weitere Verbindungen, die zur Bestimmung der Quantität der Bindung der beiden Rezeptoren an die Mikropartikel und Prokoagulationszellen erforderlich sind.
  30. Prüfset zur Bestimmung Phospholipid-bindender Antikörper, umfassend:
    Mikropartikel und/oder Prokoagulationszellen oder synthetische Phospholipid-haltige Liposomen;
    sowie weitere Verbindungen, die zum Bestimmen der Bindung Phospholipid-bindender Antikörper auf den Mikropartikeln, Prokoagulationszellen oder synthetischen Phospholipid-haltigen Liposomen erforderlich sind.
EP95942622A 1994-07-23 1995-07-19 Verfahren zur bestimmung des präthrombotischen status Expired - Lifetime EP0772778B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP95942622A EP0772778B1 (de) 1994-07-23 1995-07-19 Verfahren zur bestimmung des präthrombotischen status

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94111514 1994-07-23
EP94111514 1994-07-23
PCT/EP1995/002846 WO1996003655A1 (en) 1994-07-23 1995-07-19 Method for the determination of the prethrombotic state
EP95942622A EP0772778B1 (de) 1994-07-23 1995-07-19 Verfahren zur bestimmung des präthrombotischen status

Publications (2)

Publication Number Publication Date
EP0772778A1 EP0772778A1 (de) 1997-05-14
EP0772778B1 true EP0772778B1 (de) 1999-10-27

Family

ID=8216140

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95942622A Expired - Lifetime EP0772778B1 (de) 1994-07-23 1995-07-19 Verfahren zur bestimmung des präthrombotischen status

Country Status (7)

Country Link
US (1) US7005271B1 (de)
EP (1) EP0772778B1 (de)
JP (1) JP3574659B2 (de)
AT (1) ATE186121T1 (de)
DE (1) DE69513027T2 (de)
ES (1) ES2139957T3 (de)
WO (1) WO1996003655A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284475B1 (en) * 1997-07-11 2001-09-04 Mount Sinai School Of Medicine Of The City Of New York Assays for diagnosis of thrombophilic disease
US7687272B1 (en) 1998-01-12 2010-03-30 Henry Buchwald Method and apparatus for determining blood oxygen transport
AU1218900A (en) * 1998-10-23 2000-05-15 Accumetrics, Inc. Method for determining platelet count
US6806091B1 (en) 1999-01-12 2004-10-19 Henry Buchwald Method and apparatus for determining blood oxygen transport
DE60138111D1 (de) * 2000-07-21 2009-05-07 Chemo Sero Therapeut Res Inst Verfahren zur reinigung eines kalziumionen-bindenden proteins
EP1379266B1 (de) 2001-02-21 2007-04-18 SurroMed, Inc. Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US6746872B2 (en) * 2002-01-16 2004-06-08 Lifescan, Inc. Control compositions and methods of use for coagulation tests
WO2005007868A2 (en) 2003-07-08 2005-01-27 Accumetrics, Inc. Controlled platelet activation to monitor therapy of adp antagonists
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
CA2640167A1 (en) * 2006-01-27 2007-08-02 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining blood coagulation
FR2917172B1 (fr) * 2007-06-07 2014-01-03 Inst Nat Sante Rech Med Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation
CA2733672C (en) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
EP2598652A4 (de) 2010-07-29 2014-04-30 Shire Human Genetic Therapies Tests zum nachweis von glykosaminoglykanen
US20150017672A1 (en) * 2012-02-01 2015-01-15 Shire Human Genetic Therapies Inc. Assays for detection of glycosaminoglycans

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668638A (en) 1983-03-24 1987-05-26 The Liposome Company, Inc. Liposome composition for lupus assay
FR2621128B1 (fr) 1987-09-30 1994-05-06 Sanofi Trousse et methode de dosage immunometrique applicables a des cellules entieres
US5340719A (en) 1990-11-23 1994-08-23 Corporation Coulter Method and apparatus for optically screening microscopic cells
US5266462A (en) * 1992-06-03 1993-11-30 Baxter Diagnostics Inc. Measurement of platelet activities
CA2072548A1 (en) 1992-06-26 1993-12-27 Michael W. Stewart Methods for determining antiphospholipid antibodies
DE4229933A1 (de) * 1992-09-08 1994-03-10 Max Planck Gesellschaft Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
US5472852A (en) * 1993-09-15 1995-12-05 Oklahoma Medical Research Foundation Assay for detection of selective Protein C inhibition by patients

Also Published As

Publication number Publication date
EP0772778A1 (de) 1997-05-14
JP3574659B2 (ja) 2004-10-06
JPH10503023A (ja) 1998-03-17
WO1996003655A1 (en) 1996-02-08
DE69513027T2 (de) 2000-03-16
DE69513027D1 (de) 1999-12-02
US7005271B1 (en) 2006-02-28
ES2139957T3 (es) 2000-02-16
ATE186121T1 (de) 1999-11-15

Similar Documents

Publication Publication Date Title
EP0772778B1 (de) Verfahren zur bestimmung des präthrombotischen status
Wood et al. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations
Bevers et al. Defective Ca (2+)-induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study of the red blood cells of Scott syndrome
Suzuki et al. Biotinylated erythrocytes: in vivo survival and in vitro recovery
Sinauridze et al. Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets
US7282368B2 (en) Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome
Galili et al. Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction.
Leslie et al. Coagulation changes during the steady state in homozygous sickle‐cell disease in Jamaica
US20070141055A1 (en) Methods and compositions for protein-hydroxy apatite complexes and their application in testing and modulating immunological system including a novel in vitro test for the detection of antibodies against calcium binding protein-hydroxy apatite complexes
Dachary-Prigent et al. Physiopathological significance of catalytic phospholipids in the generation of thrombin
WO1993007491A1 (en) A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US7252959B2 (en) Assays for diagnosis of thrombophilic disease
Reverter et al. Platelet activation during hemodialysis measured through exposure of p-selectin: analysis by flow cytometric and ultrastructural techniques
US5952184A (en) Methods for determining platelet function
Michelson et al. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults
Attanasio et al. Stimulation of eryptosis by anti-A IgG antibodies
Batar et al. Simultaneous engagement of thrombin and FcγRIIA receptors results in platelets expressing high levels of procoagulant proteins
US4959308A (en) Immunoassay for antibodies binding platelets
Smink et al. Immunologic demonstration of a deficiency of Hageman factor-like material in Hageman trait
Henriksson et al. Discrepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis
Brain et al. Glycophorin A‐mediated haemolysis of normal human erythrocytes: evidence for antigen aggregation in the pathogenesis of immune haemolysis
Sadallah et al. CR1, CD35 in synovial fluid from patients with inflammatory joint diseases
Sorice et al. Anti-prothrombin but not “pure” anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibody syndrome
JP2004528534A (ja) プロテインｓ機能的アッセイ
NICHOLS et al. Bernard-Soulier syndrome: whole blood diagnostic assays of platelets

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE ES FR IT LI

17Q First examination report despatched

Effective date: 19980504

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE DIAGNOSTICS GMBH

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT CH DE ES FR IT LI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991027

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991027

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991027

REF Corresponds to:

Ref document number: 186121

Country of ref document: AT

Date of ref document: 19991115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69513027

Country of ref document: DE

Date of ref document: 19991202

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: BIANCHETTI - BRACCO - MINOJA S.R.L.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2139957

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

REG Reference to a national code

Ref country code: FR

Ref legal event code: CL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080612

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080728

Year of fee payment: 14

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090719

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120806

Year of fee payment: 18

Ref country code: DE

Payment date: 20120625

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140201

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69513027

Country of ref document: DE

Effective date: 20140201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731